Sign inJoin free

Watch / Small Cap

Not so Little Green Pharma

7 Nov 20245:56

Not so Little Green Pharma

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Paul Long CEO of Little Green Pharma (ASX:LGP) reports record revenue of over $10 million, fuelled by robust European growth and their first positive cash flow. Little Green Pharma's success stems from steady increases in Australia and significant orders in Germany, Denmark, and the UK.

Paul sees continued opportunities for growth with a strong position in the fast-growing Australian market and emerging European markets. The German market, in particular, shows potential for increased demand due to recent regulatory changes, positioning the company favourably.

Operational efficiencies remain a focus for Little Green Pharma (ASX:LGP) to enhance cash flow positivity. The company's strategic edge is further strengthened by Thorney Investment raising its stake. Paul emphasizes growth prospects in both mature markets and exciting new sectors like psychedelics.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy